World's 5th largest specialty generic company
Sun Pharmacueticals and Ranbaxy Laboratories announced that they have entered into definitive agreements pursuant to which Sun Pharma will acquire 100% of Ranbaxy in an all stock transaction.Under the agreements, Ranbaxy shareholders will receive 0.8 shares of Sun Pharma for each equity share of Ranbaxy.
The exchange ratio represents an implied value of Rs 457 for each Ranbaxy shares.
This will create the fifth largest specialty generics company in the world and the largest pharma company in India. On pro-forma basis, the combined entity's revenue is estimated at US $ 4.2 billion with EBITDA of US $ 1.2 billion for the 12 month period ended 31 December 2013.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app